Hot Features
Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing immune-oncology technologies to treat cancers. Its DNase technology targets neutrophil extracellular traps (NETS), which are involved in cancer growth, metastasis, and progression, and contribute to immunotherapy, chemother... Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing immune-oncology technologies to treat cancers. Its DNase technology targets neutrophil extracellular traps (NETS), which are involved in cancer growth, metastasis, and progression, and contribute to immunotherapy, chemotherapy, and radiotherapy resistance. The company’s product pipeline includes XBIO-015 for the treatment of pancreatic carcinoma and solid tumors; XBIO-020 for the treatment of solid tumors; and ErepoXen, which uses PolyXen platform technology for the treatment of anemia in chronic kidney disease (CKD) patients. It has a sublicensing agreement with Takeda Pharmaceutical Co. Ltd, as well as various research, development, license and supply agreements with Serum Institute of India, PJSC Pharmsynthez, and SynBio, LLC. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.29 | -8.68263473054 | 3.34 | 3.495 | 2.995 | 17823 | 3.30391825 | CS |
| 4 | -0.03 | -0.974025974026 | 3.08 | 3.495 | 2.75 | 13972 | 3.22369646 | CS |
| 12 | -0.11 | -3.48101265823 | 3.16 | 3.6799 | 2.65 | 15013 | 3.17264389 | CS |
| 26 | 0.68 | 28.6919831224 | 2.37 | 3.6799 | 1.9 | 22255 | 2.66376058 | CS |
| 52 | -0.09 | -2.86624203822 | 3.14 | 13.93 | 1.9 | 240259 | 8.92296234 | CS |
| 156 | -0.26 | -7.85498489426 | 3.31 | 13.93 | 1.9 | 87492 | 8.51704224 | CS |
| 260 | 0.77 | 33.7719298246 | 2.28 | 13.93 | 0.240101 | 616505 | 3.43182625 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.